Alvotech

ALVO

Company Profile

  • Business description

    Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

  • Contact

    9, rue de Bitbourg
    LuxembourgL-1273
    LUX

    T: +352 4224500

    https://www.alvotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    1,460

Stocks News & Analysis

stocks

Beaten down real estate share receives legal blow

Real estate share remains cheap despite losing airport legal battle.
stocks

OpenAI joins the mega-AI lab IPO race, but timing is uncertain

The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.
stocks

What happens if Tesla and SpaceX merge?

We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,006.1029.100.32%
CAC 408,350.87150.081.83%
DAX 4024,635.30425.591.76%
Dow JONES (US)51,202.26353.510.70%
FTSE 10010,471.72167.841.63%
HKSE24,718.10468.811.93%
NASDAQ25,888.8479.180.31%
Nikkei 22566,020.041,802.772.81%
NZX 50 Index13,393.87191.711.45%
S&P 5007,431.4637.160.50%
S&P/ASX 2008,804.0030.500.35%
SSE Composite Index4,031.5144.501.12%

Market Movers